Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company, has been making significant strides in the healthcare sector, particularly in the realm of helical peptide therapeutics. Based in Cambridge, Massachusetts, and listed on the New York Stock Exchange, Parabilis has carved a niche for itself by focusing on the development of therapeutics targeting proteins traditionally deemed undruggable. This innovative approach is facilitated through its proprietary Helicon discovery platform, which has become a cornerstone of its research and development efforts.
As of September 24, 2026, Parabilis Medicines’ stock closed at $31.2, reflecting a market capitalization of approximately $3.85 billion. Despite a challenging year, with the stock reaching a 52-week high of $42.49 on September 17, 2026, and a low of $24.51 on June 14, 2026, the company’s strategic initiatives and pipeline developments have kept investor interest piqued. The company’s price-to-earnings ratio stands at -1.78, indicative of its current phase of growth and investment in research and development over immediate profitability.
Central to Parabilis Medicines’ pipeline is FOG-001, a lead clinical program that acts as a TCF-blocking beta-catenin inhibitor, targeting cancer treatment. This program exemplifies the company’s commitment to addressing complex diseases through innovative therapeutic mechanisms. FOG-001’s development is a testament to Parabilis’ focus on intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, areas that hold significant promise for advancing cancer treatment.
The integration of artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization underscores Parabilis Medicines’ forward-thinking approach. By leveraging these technologies, the company aims to enhance the efficiency and effectiveness of its research and development processes, potentially accelerating the path to market for its therapeutic candidates.
Parabilis Medicines serves a diverse clientele within the healthcare and life sciences industries, including clinical research organizations and medical professionals specializing in oncology and cancer treatment. This broad client base not only underscores the company’s pivotal role in the healthcare sector but also highlights its potential to impact a wide range of therapeutic areas.
Founded in 2015, Parabilis Medicines has rapidly evolved from a nascent biopharmaceutical company to a key player in the development of helical peptide therapeutics. Its focus on targeting traditionally undruggable proteins, combined with its innovative use of technology in drug discovery and development, positions Parabilis Medicines at the forefront of the biopharmaceutical industry. As the company continues to advance its pipeline and expand its therapeutic offerings, it remains a company to watch for those interested in the future of healthcare and life sciences innovation.
